ArticleBreast (Edinburgh, Scotland)2026
Fertility and ovarian function preservation in young women with breast cancer: A joint analysis of the Joven & Fuerte and PREFER prospective studies.
Article in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPotential infertility and premature ovarian insufficiency represent notable concerns for young women with breast cancer (YWBC) undergoing chemotherapy. Cryopreservation techniques and temporary ovarian suppression with GnRH agonists (GnRHa) can be offered for fertility preservation (FP) and/or ovarian protection. This joint analysis of the Joven & Fuerte and PREFER multicenter prospective studies compared the uptake of these strategies and associated factors among Mexican and Italian YWBC.
methodsFemales ≤40 years diagnosed with non-metastatic BC from 2014 to 2019, who were offered FP strategies before (neo)adjuvant chemotherapy were included. Uptake of GnRHa for ovarian protection and cryopreservation procedures and reasons for their non-utilization were examined.
resultsAmong 485 patients (74 % from Mexico; 26 % from Italy), cryopreservation techniques were used in 8 % of Mexican patients and 25 % of Italian patients (p < 0.001). Methods in Mexico and Italy, respectively, comprised oocyte (50 % and 87 %), embryo (53 % and 0 %), and ovarian tissue (0 % and 16 %) cryopreservation. GnRHa were used in 98 % of Italian patients and 6 % of Mexican patients. Cryopreservation uptake was associated with younger age (OR 1.2, 95 %CI 1.1-1.2), childlessness (OR 21.8, 95 %CI 10.0-47.6), stage I-II BC (OR 3.1, 95 %CI 1.5-6.3), private healthcare in Mexico (OR 3.0, 95 %CI 1.1-8.1), and unpartnered status in Italy (OR 5.4, 95 %CI 2.2-13.2).
conclusionFP and ovarian protection uptake were markedly higher in Italy than Mexico, possibly reflecting divergent social and healthcare contexts, though cryopreservation remained underutilized in both countries. Improved access to oncofertility services is warranted to provide comprehensive care aligned with the personal needs and life plans of YWBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.